However, only 21% of pancreatic cancer patients are sensitive to platinum-based chemotherapy, and the objective response rate to platinum-based regimens is only ~50%, even among pancreatic cancer patients with germline BRCA or PALB2 mutations [20]. This evidence concerns the gene PALB2 and familial pancreatic carcinoma.